Dexmedetomidine Infusion as a Novel Supportive Therapy for Fluphenazine-Induced Neuroleptic Malignant Syndrome in a 10-Year-Old Boy: A Case Report and Review of Literature

Caroline Yu; Rajat Kaul; Waseem Ostwani

doi:10.1055/s-0040-1721380

Journal of Pediatric Neurology, Table of Contents

Journal of Pediatric Neurology 2021; 19(06): 425-427
DOI: 10.1055/s-0040-1721380

Case Report

Dexmedetomidine Infusion as a Novel Supportive Therapy for Fluphenazine-Induced Neuroleptic Malignant Syndrome in a 10-Year-Old Boy: A Case Report and Review of Literature

Caroline Yu

¹Department of Pediatrics, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States

,

Rajat Kaul

²Department of Pediatrics, Division of Pediatric Hospitalist Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States

,

Waseem Ostwani

³Department of Pediatrics, Division of Pediatric Critical Care Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States

› Author Affiliations

Abstract

A 10-year-old male child patient developed symptoms of neuroleptic malignant syndrome (NMS) 1 month following initiation of fluphenazine for behavioral therapeutic management. Dexmedetomidine infusion was able to adequately control the symptoms of NMS with resolution of encephalopathy. This was the first report of novel dexmedetomidine utilization for the treatment of NMS. We suggest using dexmedetomidine as an adjunctive agent to control NMS symptomatology without attendant risk of respiratory depression.

Keywords

neuroleptic malignant syndrome - fluphenazine - dexmedetomidine

Full Text

References

References
1 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington, DC: American Psychiatric Association; 2013
2 Numa A. Neuroleptic malignant syndrome in children. Med J Aust 1991; 155 (06) 417-419
3 Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther 2002; 24 (01) 21-37
4 Belvederi Murri M, Guaglianone A, Bugliani M. et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D 2015; 15 (01) 45-62
5 Sharma R, Trappler B, Ng YK, Leeman CP. Risperidone-induced neuroleptic malignant syndrome. Ann Pharmacother 1996; 30 (7-8): 775-778
6 Zalsman G, Lewis R, Konas S. et al. Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents. Int J Adolesc Med Health 2004; 16 (02) 179-182
7 Mané A, Baeza I, Morer A, Lázaro ML, Bernardo M. Neuroleptic malignant syndrome associated with risperidone in a male with early-onset schizophrenia. J Child Adolesc Psychopharmacol 2005; 15 (06) 844-845
8 Aruna AS, Murungi JH. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. Ann Pharmacother 2005; 39 (06) 1131-1135
9 Aboraya A, Schumacher J, Abdalla E. et al. Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. W V Med J 2002; 98 (02) 63-65
10 Chungh DS, Kim BN, Cho SC. Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. J Psychopharmacol 2005; 19 (04) 422-425
11 Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142 (10) 1137-1145
12 Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004; 26 (07) 1105-1108
13 Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004; 22 (02) 389-411
14 Strawn JR, Keck Jr PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164 (06) 870-876
15 Gratz SS, Levinson DF, Simpson GM. The treatment and management of neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16 (04) 425-443
16 Balzan MV. The neuroleptic malignant syndrome: a logical approach to the patient with temperature and rigidity. Postgrad Med J 1998; 74 (868) 72-76
17 Ty EB, Rothner AD. Neuroleptic malignant syndrome in children and adolescents. J Child Neurol 2001; 16 (03) 157-163
18 Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatr 2008; 69 (07) 1157-1165
19 Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatr 1989; 146 (06) 717-725
20 Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?. Br J Psychiatr 1991; 159: 709-712
21 Hammerman S, Lam C, Caroff SN. Neuroleptic malignant syndrome and aripiprazole. J Am Acad Child Adolesc Psychiatry 2006; 45 (06) 639-641
22 Walker A, Delle Donne A, Douglas E, Spicer K, Pluim T. Novel use of dexmedetomidine for the treatment of anticholinergic toxidrome. J Med Toxicol 2014; 10 (04) 406-410
23 Keating GM. Dexmedetomidine: a review of its use for sedation in the intensive care setting. Drugs 2015; 75 (10) 1119-1130
24 Okabe T, Takeda S, Akada S, Hongo T, Sakamoto A. Postoperative intensive care unit drug fever caused by dexmedetomidine. Anesth Analg 2009; 108 (05) 1589-1591